Cerebral venous thrombosis (CVT) is caused by partial or complete occlusion of the major
cerebral venous sinuses or the smaller feeding cortical veins which predispose to the risk of …

Cerebral venous thrombosis (CVT) causes significant disability and mortality. Current
guidelines for CVT management support the initial use of unfractionated heparin or low …

Background: High level evidence for direct oral anticoagulants (DOACs) in patients with
cerebral venous thrombosis is lacking. We performed a systematic review and meta-analysis …

Background: A small randomized controlled trial suggested that dabigatran may be as
effective as warfarin in the treatment of cerebral venous thrombosis (CVT). We aimed to …

Objectives Current guidelines do not recommend direct oral anticoagulants (DOACs) to treat
cerebral venous thrombosis (CVT) despite their benefits over standard therapy. We …

Background: Cerebral venous thrombosis (CVT) is an uncommon neurological condition
usually treated with heparin followed by oral vitamin K antagonists (VKAs). In patients with …

Introduction Current guidelines recommend that patients with cerebral venous thrombosis
(CVT) should be treated with vitamin K antagonists (VKAs) for 3–12 months. Direct oral …

BACKGROUND: Emerging data suggest that direct oral anticoagulants may be a suitable
choice for anticoagulation for cerebral venous thrombosis (CVT). However, conducting high …

Rationale After a cerebral vein thrombosis, there is an increased risk of further venous
thromboembolic events. The optimal duration of anticoagulation after cerebral vein …

Rationale To prevent recurrent venous thrombotic events after acute cerebral venous or
dural sinus thrombosis, guidelines recommend long-term oral anticoagulation with vitamin K …